| Literature DB >> 31458269 |
Nitesh Kumar Nandwana1, Rajnish Prakash Singh1, Om P S Patel1, Shiv Dhiman1, Hitesh Kumar Saini1, Prabhat N Jha1, Anil Kumar1.
Abstract
A new class ofEntities:
Year: 2018 PMID: 31458269 PMCID: PMC6643530 DOI: 10.1021/acsomega.8b01592
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Antimicrobial agents with indole and quinazoline motifs and designed imidazo/benzimidazo[1,2-c]quinazolines.
Scheme 1Synthesis of 2-(2-Bromoaryl)-1H-imidazole and 2-(2-Bromophenyl)-1H-benzo[d]imidazole
Synthesis of Fused Imidazo/Benzimidazo[1,2-c]quinazolines (8)a,b
Reaction conditions: 5 (1.0 mmol), 6 (1.2 mmol), CuI (20 mol %), K2CO3 (2.0 mmol), and DMF (2.0 mL) under air at 150 °C for 2 h followed by the addition of Cu(OAc)2·H2O (0.5 mmol), 150 °C, 2–5 h.
Isolated yield.
Antimicrobial Activity of Fused Imidazo/Benzimidazo[1,2-c]quinazolines (8)a
| MIC (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|
| Bacteria | | ||||||
| Gram negative | Gram positive | fungi | |||||
| compounds | |||||||
| >32 | >32 | 32 | 64 | 64 | >32 | >32 | |
| 64 | >32 | 64 | 32 | 32 | |||
| 64 | >64 | 64 | >64 | 64 | 128 | >64 | |
| 32 | 32 | >32 | 32 | 32 | |||
| >64 | 64 | 64 | >32 | >32 | 64 | 64 | |
| >32 | 32 | >32 | 32 | 32 | 32 | 32 | |
| >16 | 32 | 32 | >16 | >16 | >32 | >32 | |
| 32 | >32 | 32 | 32 | >32 | >128 | >128 | |
| >16 | 16 | 16 | >16 | >16 | 64 | >64 | |
| 32 | >32 | >32 | >32 | >32 | 32 | 32 | |
| 32 | 32 | 32 | 32 | >32 | 64 | 64 | |
| 64 | 64 | >64 | >32 | >32 | 128 | 128 | |
| >8 | >8 | >8 | |||||
| 8 | 8 | ||||||
| 16 | 16 | 16 | 16 | 16 | 32 | 32 | |
| 8 | |||||||
| 16 | >16 | >16 | 16 | >16 | >16 | >16 | |
| ciprofloxacin | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | ||
| amphotericin B | 30 | 30 | |||||
MIC: minimum inhibitory concentration in μg/mL.
No activity.
Figure 2Bactericidal assay against P. putida for compounds 8ga, 8gc, and 8gd.
Figure 3Live–dead bacterial cell screening by compounds 8ga, 8gc, and 8gd using AO/Et·Br dual staining.
Figure 4Evaluation of ROS production against P. putida using the fluorescent dye DCFH-DA as a probe.
Figure 5Hemolytic activity on human RBCs using 8aa–8gd at 100 μM. Data were analyzed by mean ± SD (standard deviation) of triplicate (n = 3) samples.
Figure 6Hemolytic activity of compound 8ga on human RBCs at different concentrations 20–100 μM. Data were analyzed by mean ± SD (standard deviation) of triplicate (n = 3) samples.
Figure 7Biofilm inhibition assay against strain S. aureus by 8aa–8gd at 50 μg/mL. All experiments were carried out in triplicates, and the values are indicated as mean ± SD.